Rapid Conjugate Vaccine Manufacturing Method, Inventprise

← USPTO Patent Applications

Methods for the Rapid Manufacture of Conjugate Vaccines that Elicit Robust Immune Responses

Application US20260097114A1 Kind: A1 Apr 09, 2026

Assignee

Inventprise, Inc.

Inventors

Subhash V. Kapre

Abstract

The disclosures of the invention are directed to the manufacture of effective, affordable vaccines that are globally accessible. Using a platform conjugation technology, highly immunogenic conjugate vaccines were produced that elicit broad cross-neutralization to variants of concern (VOC), manufactured cheaply compared to mRNA vaccines. Protein-protein conjugates and Toll-Like Receptor (TLR) agonist adjuvants were shown to enhance immunogenicity and induce broad cross-protection against VOC, a characteristic lacking in early mRNA COVID-19 vaccines. Murine nAb titers from Beta-only conjugates were equivalent between Beta, Delta, Omicron BA.1, BA.2, and BA.4/BA.5, which were circulating up to three years after the antigenic strain. Additionally, Beta-Delta bivalent conjugate vaccines readily prevented disease in hamster challenge, which demonstrates a vaccine with remarkably broad cross-protection and potential to protect for extended periods despite mutations, without requiring expensive boosters or antigen adaption. This vaccine can be produced in our highly automated, large-scale manufacturing facility enabling economical production of inexpensive, effective vaccines for high-need areas.

CPC Classifications

A61K 39/215 A61K 9/0019 A61K 39/02 A61K 39/385 A61K 39/39 A61P 31/14 A61K 2039/54 A61K 2039/545 A61K 2039/55505 A61K 2039/55555 A61K 2039/55572 A61K 2039/55577 A61K 2039/6037 A61K 2039/70

Filing Date

2025-10-07

Application No.

19352239

View original document →